A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2018
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sorafenib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 17 Sep 2018 Planned End Date changed from 1 Apr 2019 to 30 Apr 2019.
- 17 Sep 2018 Planned primary completion date changed from 1 Apr 2019 to 30 Apr 2019.
- 14 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019.